Crenezumab Overview

Introduction of Crenezumab

Crenezumab is a fully humanized monoclonal antibody (from mouse) against human 1-42 β-amyloid (Aβ), which is being investigated as a treatment of Alzheimer's disease. Crenezumab recognizes multiple forms of aggregated Aβ, including oligomeric and fibrillar species and amyloid plaques with high affinity, and monomeric Aβ with low affinity. Crenezumab remains the only antibody that targets the mid-region of Aβ peptide and binds to multiple aggregated forms with dissociating effects. It was developed by Swiss-based biopharmaceutical company AC Immune using an IgG4 backbone, and it was licensed to Genentech, Inc. in 2006.

Mechanism of Action of Crenezumab

The precise mechanism by which Crenezumab exerts its therapeutic effects in AD is unknown. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting Aβ peptides. It was engineered to clear excess Aβ while exerting reduced subsequent effector function on microglia; the rationale is to stimulate amyloid phagocytosis while limiting release of inflammatory cytokines as a way to avoid side effects such as vasogenic edema.

Fig.1 Mechanism of Action of Crenezumab

Clinical Projects of Crenezumab*

What We Provide

Therapeutic Antibody

Crenezumab

We provide high-quality Crenezumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resource
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Crenezumab

For research use only. Not intended for any clinical use.